OHSU has been awarded two grants totaling $62 million from the National Center for Advancing Translational Sciences, to help bridge basic science and clinical research.
The first FDA-approved gene transfer therapy for patients with acute lymphoblastic leukemia will be available at a handful of approved hospitals, including OHSU Doernbecher.
Scientists have uncovered two related cytokines and associated genetic markers that may explain why some people develop progressive multiple sclerosis, or MS.
OHSU Hospital ranks 12th in the nation for “superior performance" in providing high-quality care, based on mortality, safety, efficiency, effectiveness, patient centeredness and equity, according to the 2017 Vizient Quality and Accountability Study.